Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (1177)	4/16/1998 1:20:00 AM
From: The Perfect Hedge	Respond to of 9523

B- how bout the latest Peabody report?TIA.GD

To: BigKNY3 who wrote (1177)	4/16/1998 6:44:00 AM
From: EyeDrMike	Read Replies (1) \| Respond to of 9523

<<), exactly one patient discontinued therapy due to abnormal vision>> In fixed-dosed trials, PFE reported 11% of patients had visual abnormalities. And this percentage increases in frequency at higher dosages. PS. BigNYK3, amazing. I thought you didn't read my posts. How did i get such an impression?? You never answered my questions. Is PFE overvalued at PE of 57 with a growth rate of 16%? Will Viagra have 5 billion dollars in annual sales? Why didn't PFE breakdown ED type in their trials? Why was an erection necessary to be included in these trials? Why was the age range <18 to 80> so broad? Why was the main trials "flexible-dose" ? There were a few other questions. You never responded to a single one. My post stands in regards to the blindness question. It comes from scientific studies, and reports. All footnoted at the bottom. Looks kinda serious to me. Mike